Annex 2. ENCePP Checklist for Study Protocols

Study title: METFORMIN USE IN RENAL IMPAIRMENT

Study reference number:

ENCEPP/SDPP/5249

Section 1: Milestones	Yes	No	N/A	Page Number(s)
1.1 Does the protocol specify timelines for				
1.1.1 Start of data collection[1]	☐	☐	☒	
1.1.2 End of data collection[2]	☒	☐	☐	7
1.1.3 Study progress report(s)	☒	☐	☒	7
1.1.4 Interim progress report(s)	☒	☐	☐	7
1.1.5 Registration in the EU PAS register	☐	☐	☒	
1.1.6 Final report of study results.	☒	☐	☐	7

Comments:

Section 2: Research question	Yes	No	N/A	Page Number(s)
2.1 Does the formulation of the research question and objectives clearly explain:				
2.1.1 Why the study is conducted? (e.g. to address an important public health concern, a risk identified in the risk management plan, an emerging safety issue)	☒	☐	☐	8
2.1.2 The objective(s) of the study?	☒	☐	☐	8,9

---

[1] Date from which information on the first study is first recorded in the study dataset or, in the case of secondary use of data, the date from which data extraction starts.
[2] Date from which the analytical dataset is completely available.

Section 2: Research question	Yes	No	N/A	Page Number(s)
2.1.3 The target population? (i.e. population or subgroup to whom the study results are intended to be generalised)	☒	☐	☐	8
2.1.4 Which formal hypothesis(-es) is (are) to be tested?				
2.1.5 If applicable, that there is no *a priori* hypothesis?	☐	☐	☒	
	☒	☐	☐	

Comments:

Section 3: Study design	Yes	No	N/A	Page Number(s)
3.1 Is the study design described? (e.g. cohort, case-control, randomised controlled trial, new or alternative design)	☒	☐	☐	9
3.2 Does the protocol specify the primary and secondary (if applicable) endpoint(s) to be investigated?	☒	☐	☐	10,11
3.3 Does the protocol describe the measure(s) of effect? (e.g. relative risk, odds ratio, deaths per 1000 person-years, absolute risk, excess risk, incidence rate ratio, hazard ratio, number needed to harm (NNH) per year)	☒	☐	☐	15,16

Comments:

Section 4: Source and study populations	Yes	No	N/A	Page Number(s)
4.1 Is the source population described?	☒	☐	☐	9
4.2 Is the planned study population defined in terms of:				
4.2.1 Study time period?	☒	☐	☐	9,10

Section 4: Source and study populations	Yes	No	N/A	Page Number(s)
4.2.2 Age and sex?	☒	☐	☐	9,10
4.2.3 Country of origin?	☒	☐	☐	9,10
4.2.4 Disease/indication?	☒	☐	☐	9,10
4.2.5 Co-morbidity?	☒	☐	☐	9,10
4.2.6 Seasonality?	☐	☐	☒	
4.3 Does the protocol define how the study population will be sampled from the source population? (e.g. event or inclusion/exclusion criteria)	☒	☐	☐	10

Comments:

Section 5: Exposure definition and measurement	Yes	No	N/A	Page Number(s)
5.1 Does the protocol describe how exposure is defined and measured? (e.g. operational details for defining and categorising exposure)	☒	☐	☐	10,11
5.2 Does the protocol discuss the validity of exposure measurement? (e.g. precision, accuracy, prospective ascertainment, exposure information recorded before the outcome occurred, use of validation sub-study)	☒	☐	☐	10,11,12,18
5.3 Is exposure classified according to time windows? (e.g. current user, former user, non-use)	☒	☐	☐	10
5.4 Is exposure classified based on biological mechanism of action and taking into account the pharmacokinetics and pharmacodynamics of the drug?	☒	☐	☐	14
5.5 Does the protocol specify whether a dose-dependent or duration-dependent response is measured?	☒	☐	☐	14

Comments:

Section 6: Endpoint definition and measurement	Yes	No	N/A	Page Number(s)
6.1 Does the protocol describe how the endpoints are defined and measured?	☒	☐	☐	10,11
6.2 Does the protocol discuss the validity of endpoint measurement? (e.g. precision, accuracy, sensitivity, specificity, positive predictive value, prospective or retrospective ascertainment, use of validation sub-study)	☒	☐	☐	11,18

Comments:

Section 7: Confounders and effect modifiers	Yes	No	N/A	Page Number(s)
7.1 Does the protocol address known confounders? (e.g. collection of data on known confounders, methods of controlling for known confounders)	☒	☐	☐	12
7.2 Does the protocol address known effect modifiers? (e.g. collection of data on known effect modifiers, anticipated direction of effect)	☒	☐	☐	12

Comments:

Section 8: Data sources	Yes	No	N/A	Page Number(s)
8.1 Does the protocol describe the data source(s) used in the study for the ascertainment of:				
8.1.1 Exposure? (e.g. pharmacy dispensing, general practice prescribing, claims data, self-report, face-to-face interview, etc.)	☒	☐	☐	12
8.1.2 Endpoints? (e.g. clinical records, laboratory markers or values, claims data, self-report, patient interview including scales and questionnaires, vital statistics, etc.)	☒	☐	☐	12
8.1.3 Covariates?				

Section 8: Data sources	Yes	No	N/A	Page Number(s)
	☒	☐	☐	12
8.2 Does the protocol describe the information available from the data source(s) on: 8.2.1 Exposure? (e.g. date of dispensing, drug quantity, dose, number of days of supply prescription, daily dosage, prescriber) 8.2.2 Endpoints? (e.g. date of occurrence, multiple event, severity measures related to event)	☒	☐	☐	12
8.2.3 Covariates? (e.g. age, sex, clinical and drug use history, co-morbidity, co-medications, life style, etc.)	☒	☐	☐	12
	☒	☐	☐	12
8.3 Is a coding system described for: 8.3.1 Diseases? (e.g. International Classification of Diseases (ICD)-10)	☒	☐	☐	12
8.3.2 Endpoints? (e.g. Medical Dictionary for Regulatory Activities (MedDRA) for adverse events) 8.3.3 Exposure? (e.g. WHO Drug Dictionary, Anatomical Therapeutic Chemical (ATC)Classification System)	☒	☐	☐	12
	☒	☐	☐	12
8.4 Is the linkage method between data sources described? (e.g. based on a unique identifier or other)	☒	☐	☐	12

Comments:

Section 9: Study size and power	Yes	No	N/A	Page Number(s)
9.1 Is sample size and/or statistical power calculated?	☒	☐	☐	13

Comments:

We estimated the number of observations available for analyses in the two databases

Section 10: Analysis plan	Yes	No	N/A	Page Number(s)
10.1 Does the plan include measurement of excess risks?	☐	☐	☒	
10.2 Is the choice of statistical techniques described?	☒	☐	☐	14
10.3 Are descriptive analyses included?	☒	☐	☐	14
10.4 Are stratified analyses included?	☒	☐	☐	14
10.5 Does the plan describe methods for adjusting for confounding?	☒	☐	☐	14
10.6 Does the plan describe methods addressing effect modification?	☐	☐	☒	

Comments:

Section 11: Data management and quality control	Yes	No	N/A	Page Number(s)
11.1 Is information provided on the management of missing data?	☐	☐	☒	
11.2 Does the protocol provide information on data storage? (e.g. software and IT environment, database maintenance and anti-fraud protection, archiving)	☒	☐	☐	14
11.3 Are methods of quality assurance described?	☒	☐	☐	16
11.4 Does the protocol describe possible quality issues related to the data source(s)?	☒	☐	☐	18
11.5 Is there a system in place for independent review of study results?	☒	☐	☐	18

Comments:

Section 12: Limitations	Yes	No	N/A	Page Number(s)
12.1 Does the protocol discuss: 12.1.1 Selection biases?	☒	☐	☐	18
12.1.2 Information biases? (e.g. anticipated direction and magnitude of such biases, validation sub-study, use of validation and external data, analytical methods)	☒	☐	☐	18
12.2 Does the protocol discuss study feasibility? (e.g. sample size, anticipated exposure, duration of follow-up in a cohort study, patient recruitment)	☒	☐	☐	13
12.3 Does the protocol address other limitations?	☒	☐	☐	18

Comments:

Section 13: Ethical issues	Yes	No	N/A	Page Number(s)
13.1 Have requirements of Ethics Committee/Institutional Review Board approval been described?	☐	☐	☒	
13.2 Has any outcome of an ethical review procedure been addressed?	☐	☐	☐	
13.3 Have data protection requirements been described?	☒	☐	☐	19

Comments:

Section 14: Amendments and deviations	Yes	No	N/A	Page Number(s)
14.1 Does the protocol include a section to document future amendments and deviations?	☒	☐	☐	7

Comments:

Section 15: Plans for communication of study results	Yes	No	N/A	Page Number(s)
15.1 Are plans described for communicating study results (e.g. to regulatory authorities)?	☒	☐	☐	7,19
15.2 Are plans described for disseminating study results externally, including publication?	☒	☐	☐	19

Comments:

Name of the main author of the protocol: Christian Fynbo Christiansen, MD, PhD

Date: 30/110/.

27/11-2013

Signature: _____